Clinical trialNCT06015659Active, not recruitingPhase 2Interventional

ZN-c3 + Gemcitabine in Pancreatic Cancer

SponsorBrandon Huffman, MDEnrollment12Advanced Pancreatic AdenocarcinomaPancreatic CancerPancreatic Ductal Adenocarcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being done to test the safety and effectiveness of combining ZN-c3 and Gemcitabine in participants with pancreatic cancer. The names of the study drugs involved in this study are: * ZN-c3 (a small molecule inhibitor of the WEE1 tyrosine kinase) * Gemcitabine (a nucleoside metabolic inhibitor)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Brandon Huffman, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Dana Farber Cancer Institute
Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

GemzarZentalis

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Nov 2023
Primary completion: 6 Aug 2025
Completion: 1 Jun 2027
Last update posted: 4 May 2026
Registered enrollment: 12
Registry id: NCT06015659

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.